FAQ: What lifestyle changes are essential for managing cirrhosis effectively?
GHAPPcast12 Helmi 2025

FAQ: What lifestyle changes are essential for managing cirrhosis effectively?

In this video, Sherona Bau, NP, from the Pfleger Liver Institute at UCLA, discusses the essential lifestyle changes for effectively managing cirrhosis. Maintaining a healthy lifestyle is key to slowing disease progression and preventing complications. One of the most critical recommendations is completely avoiding alcohol, as it accelerates liver damage and increases the risk of decompensation.

A low-sodium diet is also essential, with a daily limit of no more than 2,000 mg of sodium to help reduce fluid retention, leg swelling, and abdominal ascites. Patients should avoid processed and canned foods, which are often high in sodium, and eliminate raw or undercooked shellfish to prevent infections. Additionally, reducing sugary drinks, refined sugar, and red meat intake can support overall liver health.

It’s also important to avoid NSAIDs (nonsteroidal anti-inflammatory drugs), as they can increase the risk of kidney injury, and refrain from using herbal supplements without consulting a healthcare provider. Lastly, regular physical activity—such as walking 20 to 30 minutes daily—can help maintain overall health and improve disease outcomes.


Making these lifestyle changes can significantly improve quality of life and liver function for patients with cirrhosis. Watch this video for expert insights, and visit the GHAPP website or download the GHAPP ACE app for more information.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(155)

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Kesä 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Touko 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Touko 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Touko 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Touko 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Touko 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Huhti 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Huhti 23min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
rss-pitaisko-erota
psykopodiaa-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
tiedenaiset-podcast
voi-hyvin-meditaatiot-2
puhu-muru
rss-kuumilla-aalloilla
rss-pt-paahtio
rss-narsisti
meditaatiot-suomeksi
terapiassa
rss-uplevel-by-sonja-hannus
katilon-kahvitunti
fitnessvastaanotto
paritellen
rss-nautinto
rss-terapiaklubi
junnut-pelissa
monisuhteellista